- Home
- MKTX vs ROIV Comparison
MKTX vs ROIV Comparison
Compare MKTX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKTX | ROIV |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 23.2B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MKTX | ROIV |
|---|---|---|
| Price | $116.84 | $34.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $204.88 | $28.94 |
| AVG Volume (30 Days) | 791.1K | ★ 5.8M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.20 | N/A |
| Revenue | ★ $397,471,000.00 | $8,260,000.00 |
| Revenue This Year | $10.14 | N/A |
| Revenue Next Year | $7.22 | $744.61 |
| P/E Ratio | $52.99 | ★ N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $108.75 | $10.71 |
| 52 Week High | $219.18 | $35.90 |
Technical Indicators
Market Signals| Indicator | MKTX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 71.26 |
| Support Level | $111.02 | $26.65 |
| Resistance Level | $125.21 | N/A |
| Average True Range (ATR) | 4.54 | 1.17 |
| MACD | 0.95 | 0.39 |
| Stochastic Oscillator | 47.27 | 82.59 |
Price Performance
Historical ComparisonAbout MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.